Table 3.
Odds ratios (ORs) and 95% confidence intervals (CIs) of clinical status and HMGB1 rs1412125 genotypic frequencies in 579 patients with prostate cancer.
| Variable | Genotypic Frequencies | |||
|---|---|---|---|---|
| rs1412125 | TT (N = 333) | TC + CC (N = 246) | OR (95% CI) | p-Value |
| PSA at diagnosis (ng/mL) | ||||
| ≤10 | 151 (45.3%) | 119 (48.4%) | 1.00 | p = 0.470 |
| >10 | 182 (54.7%) | 127 (51.6%) | 0.885 (0.636–1.232) | |
| Pathologic Gleason grade group | ||||
| 1 + 2 + 3 | 282 (84.7%) | 202 (82.1%) | 1.00 | p = 0.409 |
| 4 + 5 | 51 (15.3%) | 44 (17.9%) | 1.204 (0.774–1.874) | |
| Clinical T stage | ||||
| 1 + 2 | 284 (85.3%) | 217 (88.2%) | 1.00 | p = 0.308 |
| 3 + 4 | 49 (14.7%) | 29 (11.8%) | 0.775 (0.474–1.267) | |
| Pathologic T stage | ||||
| 2 | 183 (55.0%) | 123 (50.0%) | 1.00 | p = 0.238 |
| 3 + 4 | 150 (45.0%) | 123 (50.0%) | 1.220 (0.877–1.697) | |
| Pathologic N stage | ||||
| N0 | 307 (92.2%) | 223 (90.7%) | 1.00 | p = 0.510 |
| N1 | 26 (7.8%) | 23 (9.3%) | 1.218 (0.677–2.190) | |
| Seminal vesicle invasion | ||||
| No | 260 (78.1%) | 192 (78.0%) | 1.00 | p = 0.993 |
| Yes | 73 (21.9%) | 54 (22.0%) | 1.002 (0.673–1.492) | |
| Perineural invasion | ||||
| No | 88 (26.4%) | 67 (27.2%) | 1.00 | p = 0.828 |
| Yes | 245 (73.6%) | 179 (72.8%) | 0.960 (0.662–1.392) | |
| Lymphovascular invasion | ||||
| No | 282 (84.7%) | 200 (81.3%) | 1.00 | p = 0.281 |
| Yes | 51 (15.3%) | 46 (18.7%) | 1.272 (0.821–1.970) | |
| D’Amico classification | ||||
| Low/Intermediate risk | 173 (52.0%) | 107 (43.5%) | 1.00 | p = 0.044 * |
| High risk | 160 (48.0%) | 139 (56.5%) | 1.405 (1.009–1.956) | |
The ORs and their 95% CIs were estimated by logistic regression models. * p-value < 0.05 = statistically significant.